Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Regulus Therapeutics Inc
RGLS | US
1.50
USD-0.07
-4.46%
RGLS | US
About Regulus Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.50
Open
1.58
High
1.65
Low
1.49
Regulus Therapeutics Inc. a clinical stage biopharmaceutical company focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012 an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome a life-threatening kidney disease; and RGLS8429 an anti-miR targeting miR-17 which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego California.
View LessRGLS | US
Risk
82.2
Sharpe
0.11
Luna's Score
39/100
Recommendation
Sell
Luna says (RGLS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
88.9%1 month
82.2%3 months
67.9%6 months
75.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.01
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.57
Ent. to rev.
0.66
PEG
-0.04
Other Fundamentals
EBITDA
-37.21M
MarketCap
98.20M
MarketCap(USD)
98.20M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
27.68K
Ret. on equity
-53.55
Short ratio
9.48
Short perc.
5.53
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.31
Range1M
0.43
Range3M
0.56
Volumes: Market Activity
Rel. volume
2.13
Price X volume
861.43K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | - | Par |
| Ent. to Revenue | 0.66 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.01 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 67.85 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 98.20M | - | Emerging |
